Company Overview and News

 
Newcrest grants Encounter seven JV exploration licences in Tanami gold province

2018-09-17 australianmining.com.au
Encounter Resources has received seven new exploration licences in the Tanami gold province in Western Australia as part of its joint venture (JV) agreement with Newcrest Mining.
NCMGF ENR NCM NCMGY

 
Encounter Resources finds gold anomalism in drilling near Telfer mine

2018-09-12 proactiveinvestors.com.au
Encounter Resources Ltd (ASX:ENR) has completed follow-up drilling at targets near the Telfer gold-copper mine owned by Newcrest Mining Ltd (ASX:NCM) in Western Australia.
NCMGF ENR NCM NCMGY

 
Newcrest’s gold hunt in northern Australia continues

2018-07-04 australianmining.com.au
Newcrest Mining has signed a farm-in agreement with Prodigy Gold over the Euro gold project in the Tanami region of the Northern Territory.
NCMGF ENR NCM NCMGY ABMMF ABU

1
Encounter Resources raises $2.75 million to advance its projects in Western Australia

2018-05-25 proactiveinvestors.com.au
Encounter Resources Ltd (ASX:ENR) has received firm placement commitments from professional and sophisticated investors to raise about $2.75 million at 6 cents per share.
NCMGF ENR NCM NCMGY

4
Newcrest builds Tanami presence in search of gold discoveries

2018-05-08 australianmining.com.au
Newcrest Mining and ABM Resources will together advance exploration of the Euro gold project in the Tanami in Northern Territory after signing an agreement.
NCMGF ENR NCM NCMGY NEM ABMMF ABU

1
Newcrest executes five JVs with Encounter

2018-05-03 australianmining.com.au
Newcrest Mining and Encounter Resources have formed a series of exploration joint ventures in Western Australia as a result of a project generation alliance established between the companies last year.
NCMGF ENR NCM NCMGY

1
Newcrest expands Encounter exploration alliance

2018-03-20 australianmining.com.au
Newcrest Mining is assessing two new exploration opportunities with Encounter Resources as part of their project generation alliance.
NCMGF ENR NCM NCMGY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:ENR / ENCOUNTER RESOURCES LIMITED on message board site Silicon Investor.

The Enron Scandal - Unmoderated The Enron Scandal - Unmoderated The Enron Scandal - Unmoderated Energizer (ENR) Energizer (ENR) Energizer (ENR)
E-Cat Device: Low Energy Nuclear Reaction(LENR) Devices E-Cat Device: Low Energy Nuclear Reaction(LENR) Devices E-Cat Device: Low Energy Nuclear Reaction(LENR) Devices Renren Renren Renren
V.FWY (FENRF) - FENWAY RESOURCES V.FWY (FENRF) - FENWAY RESOURCES V.FWY (FENRF) - FENWAY RESOURCES Jack Henry u0026 Associates (JKHY) Jack Henry u0026 Associates (JKHY) Jack Henry u0026 Associates (JKHY)
OpenROUTE Networks, Inc. (OPEN), formerly Proteon (PTON) OpenROUTE Networks, Inc. (OPEN), formerly Proteon (PTON) OpenROUTE Networks, Inc. (OPEN), formerly Proteon (PTON) GENROCO: OTC:BB GRCI GENROCO: OTC:BB GRCI GENROCO: OTC:BB GRCI
Enron Oil and Gas EOG Enron Oil and Gas EOG Enron Oil and Gas EOG The ENRON Scandal The ENRON Scandal The ENRON Scandal